Annual Statements Open main menu

Cardiff Oncology, Inc. - Quarter Report: 2013 March (Form 10-Q)

Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

x      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2013

 

OR

 

o         TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from             to            

 

COMMISSION FILE NUMBER 000-54556

 

TROVAGENE, INC.

(Exact Name of small business issuer as specified in its charter)

 

Delaware

 

27-2004382

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

11055 Flintkote Avenue, Suite A, San Diego, California 92121

(Address of principal executive offices) (Zip Code)

 

Issuer’s telephone Number: (858) 952-7570

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer  o

 

Accelerated filer  o

 

 

 

Non-accelerated filer  o

 

Smaller reporting company  x

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o  No x

 

As of May 9, 2013 the issuer had 15,616,400 shares of Common Stock issued and outstanding.

 

 

 



Table of Contents

 

TABLE OF CONTENTS

 

 

 

Page

 

PART I

 

Item 1.

Financial Statements

3

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operation

23

 

 

 

Item 4

Controls and Procedures

27

 

 

 

 

PART II

 

Item 1.

Legal Proceedings

28

 

 

 

Item 6.

Exhibits

28

 

2



Table of Contents

 

PART I

 

ITEM 1. FINANCIAL STATEMENTS.

 

INDEX TO FINANCIAL STATEMENTS

 

 

Page

 

 

Condensed Consolidated Balance Sheets as of March 31, 2013 (unaudited) and December 31, 2012

4

 

 

Condensed Consolidated Statements of Operations and Comprehensive Net Loss for the Three Months Ended March 31, 2013 and 2012 (unaudited) and the period August 4, 1999 (Inception) to March 31, 2013 (unaudited)

5

 

 

Condensed Consolidated Statements Stockholders’ Equity (Deficit) for the period August 4, 1999 (Inception) to March 31, 2013 (unaudited)

6

 

 

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2013 and 2012 (unaudited) and the period August 4, 1999 (Inception) to March 31, 2013 (unaudited)

14

 

 

Notes to Condensed Consolidated Financial Statements (unaudited)

16

 

3



Table of Contents

 

Trovagene, Inc. and Subsidiaries

 

(A Development Stage Company)

 

Condensed Consolidated Balance Sheets

 

 

 

March  31,

 

December 31,

 

 

 

2013

 

2012

 

 

 

(Unaudited)

 

(Audited)

 

 

 

 

 

 

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

9,164,275

 

$

10,819,781

 

Accounts receivable

 

58,064

 

168,381

 

Prepaid expenses

 

127,084

 

60,041

 

Total current assets

 

9,349,423

 

11,048,203

 

Property and equipment, net

 

330,314

 

254,742

 

Other assets

 

518,775

 

362,081

 

Total assets

 

$

10,198,512

 

$

11,665,026

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

$

323,366

 

$

175,679

 

Accrued expenses

 

852,994

 

554,691

 

Total current liabilities

 

1,176,360

 

730,370

 

Derivative financial instruments

 

7,486,485

 

8,765,628

 

Total liabilities

 

8,662,845

 

9,495,998

 

 

 

 

 

 

 

Commitments and contingencies (Note 8)

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 20,000,000 shares authorized, 78,100 and 95,600 shares outstanding at March 31, 2013 and December 31, 2012, respectively, designated as Series A Convertible Preferred Stock with liquidation preference of $780,100 and $956,000 at March 31, 2013 and December 31, 2012, respectively

 

78

 

96

 

 

 

 

 

 

 

Common stock, $0.0001 par value, 150,000,000 shares authorized, 15,516,191 and 15,478,177 issued and outstanding at March 31, 2013 and December 31, 2012, respectively

 

1,551

 

1,547

 

 

 

 

 

 

 

Additional paid-in capital

 

57,853,251

 

57,370,017

 

Deficit accumulated during development stage

 

(56,319,213

)

(55,202,632

)

Total stockholders’ equity

 

1,535,667

 

2,169,028

 

 

 

$

10,198,512

 

$

11,665,026

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4



Table of Contents

 

Trovagene, Inc. and Subsidiaries
(A Development Stage Company)

Condensed Consolidated Statements of Operations and Comprehensive Loss

 

 

 

Three
month ended March 31,

 

For the period August 4, 1999
(Inception) to

 

 

 

2013

 

2012

 

March 31, 2013

 

 

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

 

 

 

 

 

 

 

 

Royalty income

 

$

119,123

 

$

34,153

 

$

1,044,597

 

License fees

 

 

 

1,383,175

 

Milestone fees

 

 

 

150,000

 

Total revenues

 

119,123

 

34,153

 

2,577,772

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

802,245

 

337,407

 

18,251,696

 

Purchased in-process research and development expense-related party

 

 

 

2,666,869

 

General and administrative

 

1,706,717

 

826,964

 

27,626,833

 

Total operating expenses

 

2,508,962

 

1,164,371

 

48,545,398

 

Operating loss

 

(2,389,839

)

(1,130,218

)

(45,967,626

)

Other income (expense):

 

 

 

 

 

 

 

Interest income

 

 

 

266,883

 

Interest expense

 

 

 

(1,325,372

)

Gain on sale of equipment

 

 

 

4,000

 

Amortization of deferred debt costs and original issue discount

 

 

 

(2,346,330

)

Change in fair value of derivative instruments

 

1,279,143

 

(32,424

)

(4,215,656

)

Gain on extinguishment of debt

 

 

 

623,383

 

Liquidated damages and other forbearance agreement settlement costs

 

 

 

(1,758,111

)

Net loss and comprehensive loss

 

(1,110,696

)

(1,162,642

)

(54,718,829

)

 

 

 

 

 

 

 

 

Preferred stock dividend

 

(5,885

)

(9,560

)

(352,043

)

Cumulative effect of early adoption of ASC 815-40 on November 1, 2006

 

 

 

(455,385

)

Series A convertible preferred stock beneficial conversion feature accreted as a dividend

 

 

 

(792,956

)

Net loss and comprehensive loss attributable to common stockholders

 

$

(1,116,581

)

$

(1,172,202

)

$

(56,319,213

)

Weighted average shares of common stock outstanding:

 

 

 

 

 

 

 

Basic and diluted

 

15,510,340

 

11,001,679

 

 

 

Net loss per common share:

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.07

)

$

(0.11

)

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5



Table of Contents

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

Condensed Consolidated Statements of Stockholders’ Equity (Deficiency)

 

 

 

Common Stock

 

Treasury Shares

 

Additional
Paid-In

 

Deferred
Stock
Based

 

Deficit
Accumulated
During
Development

 

Total
Stockholders’
Equity

 

 

 

Shares

 

Amount

 

Shares

 

Amount

 

Capital

 

Compensation

 

Stage

 

(Deficiency)

 

Balance, August 4, 1999 (Inception)

 

0

 

$

0

 

0

 

$

0

 

$

0

 

$

0

 

$

0

 

$

0

 

Issuance of common stock to founders for cash at $0.0012 per share

 

37,000,000

 

3,700

 

 

 

 

 

38,300

 

 

 

 

 

42,000

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(14,760

)

(14,760

)

Balance, January 31, 2000

 

37,000,000

 

$

3,700

 

0

 

$

0

 

$

38,300

 

0

 

(14,760

)

27,240

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(267,599

)

(267,599

)

Balance, January 31, 2001

 

37,000,000

 

$

3,700

 

0

 

$

0

 

$

38,300

 

0

 

(282,359

)

(240,359

)

Capital contribution of cash

 

 

 

 

 

 

 

 

 

45,188

 

 

 

 

 

45,188

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(524,224

)

(524,224

)

Balance, January 31, 2002

 

37,000,000

 

$

3,700

 

0

 

$

0

 

$

83,488

 

0

 

(806,583

)

(719,395

)

Issuance of common stock for cash at $0.003 per share

 

1,258,000

 

126

 

 

 

 

 

3,274

 

 

 

 

 

3,400

 

Capital contribution of cash

 

0

 

0

 

 

 

 

 

2,500

 

 

 

 

 

2,500

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(481,609

)

(481,609

)

Balance, January 31, 2003

 

38,258,000

 

$

3,826

 

0

 

$

0

 

$

89,262

 

0

 

(1,288,192

)

(1,195,104

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(383,021

)

(383,021

)

Balance, January 31, 2004

 

38,258,000

 

$

3,826

 

0

 

$

0

 

$

89,262

 

0

 

(1,671,213

)

(1,578,125

)

Waiver of founders’ deferred compensation

 

0

 

0

 

 

 

 

 

1,655,031

 

 

 

 

 

1,655,031

 

Private placement of common stock

 

440,868

 

44

 

 

 

 

 

2,512,906

 

 

 

 

 

2,512,950

 

Redemption of shares held by Panetta Partners, Inc.

 

(36,477,079

)

(3,648

)

 

 

 

 

(496,352

)

 

 

 

 

(500,000

)

Costs associated with recapitalization

 

 

 

 

 

 

 

 

 

(301,499

)

 

 

 

 

(301,499

)

Share exchange with founders

 

376,334

 

38

 

 

 

 

 

(38

)

 

 

 

 

0

 

Issuance of treasury shares

 

 

 

 

 

58,333

 

6

 

(6

)

 

 

 

 

0

 

Issuance of treasury shares to escrow

 

58,333

 

6

 

(58,333

)

(6

)

0

 

 

 

 

 

0

 

Issuance of common stock and warrants for cash at $11.70 per share

 

228,026

 

23

 

 

 

 

 

2,667,877

 

 

 

 

 

2,667,900

 

Issuance of 20,610 warrants to selling agents

 

 

 

 

 

 

 

 

 

403,038

 

 

 

 

 

403,038

 

Finders warrants charged to cost of capital

 

 

 

 

 

 

 

 

 

(403,038

)

 

 

 

 

(403,038

)

Deferred stock-based compensation

 

 

 

 

 

 

 

 

 

1,937,500

 

(1,937,500

)

 

 

0

 

Amortization of deferred stock-based compensation

 

 

 

 

 

 

 

 

 

0

 

245,697

 

 

 

245,697

 

Options issued to consultants

 

 

 

 

 

 

 

 

 

1,229,568

 

 

 

 

 

1,229,568

 

Warrants issued to consultants

 

 

 

 

 

 

 

 

 

2,630,440

 

 

 

 

 

2,630,440

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(5,371,027

)

(5,371,027

)

Balance, January 31, 2005

 

2,884,482

 

$

289

 

0

 

$

0

 

$

11,924,689

 

$

(1,691,803

)

$

(7,042,240

)

$

3,190,935

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6



Table of Contents

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

Condensed Consolidated Statements of Stockholders’ Equity (Deficiency)

(continued)

 

 

 

Preferred Stock

 

Common Stock

 

Treasury Shares

 

Additional
Paid-In

 

Deferred
Stock
Based

 

Deficit
Accumulated
During
Development

 

Total
Stockholders’
Equity

 

 

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Capital

 

Compensation

 

Stage

 

(Deficiency)

 

Balance, January 31, 2005

 

0

 

$

0

 

2,884,482

 

$

289

 

0

 

$

0

 

$

11,924,689

 

$

(1,691,803

)

$

(7,042,240

)

$

3,190,935

 

Private placement of common stock

 

 

 

 

 

17,094

 

2

 

0

 

$

0

 

$

199,998

 

 

 

 

 

200,000

 

Payment of selling agents fees and expenses in cash

 

 

 

 

 

 

 

 

 

 

 

 

 

(179,600

)

 

 

 

 

(179,600

)

Common stock issued to selling agents

 

 

 

 

 

4,077

 

 

 

 

 

 

 

0

 

 

 

 

 

0

 

Private placement of common stock

 

 

 

 

 

252,564

 

25

 

 

 

 

 

2,954,974

 

 

 

 

 

2,954,999

 

Payment of selling agents fees and expenses in cash

 

 

 

 

 

 

 

 

 

 

 

 

 

(298,000

)

 

 

 

 

(298,000

)

Issuance of 20,205 warrants issued to selling agents

 

 

 

 

 

 

 

 

 

 

 

 

 

222,188

 

 

 

 

 

222,188

 

Selling agents warrants charged to cost of capital

 

 

 

 

 

 

 

 

 

 

 

 

 

(222,188

)

 

 

 

 

(222,188

)

Private placement of preferred stock and warrants for cash at $10.00 per share (restated)

 

277,100

 

277

 

 

 

 

 

 

 

 

 

2,770,723

 

 

 

 

 

2,771,000

 

Accretion of preferred stock dividends (restated)

 

 

 

 

 

 

 

 

 

 

 

 

 

792,956

 

 

 

(792,956

)

0

 

Value of warrants reclassified to derivative financial instrument liability

 

 

 

 

 

 

 

 

 

 

 

 

 

(567,085

)

 

 

 

 

(567,085

)

Payment of selling agents fees and expenses in cash

 

 

 

 

 

 

 

 

 

 

 

 

 

(277,102

)

 

 

 

 

(277,102

)

Issuance of 17,572 warrants issued to selling agents

 

 

 

 

 

 

 

 

 

 

 

 

 

167,397

 

 

 

 

 

167,397

 

Selling agents warrants charged to cost of capital

 

 

 

 

 

 

 

 

 

 

 

 

 

(167,397

)

 

 

 

 

(167,397

)

Return of treasury shares from escrow

 

 

 

 

 

(58,333

)

(6

)

58,333

 

6

 

0

 

 

 

 

 

0

 

Retirement of treasury shares

 

 

 

 

 

 

 

 

 

(58,333

)

(6

)

6

 

 

 

 

 

0

 

Common stock issued for services

 

 

 

 

 

833

 

 

 

 

 

 

 

16,500

 

 

 

 

 

16,500

 

Stock-based compensation expense for non-employees

 

 

 

 

 

 

 

 

 

 

 

 

 

2,928,298

 

 

 

 

 

2,928,298

 

Amortization of deferred stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

0

 

645,832

 

 

 

645,832

 

Preferred stock dividend

 

 

 

 

 

 

 

 

 

 

 

 

 

0

 

 

 

(60,741

)

(60,741

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,844,326

)

(7,844,326

)

Balance, January 31, 2006

 

277,100

 

$

277

 

3,100,717

 

$

310

 

0

 

$

0

 

$

20,266,357

 

$

(1,045,971

)

$

(15,740,263

)

$

3,480,710

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

7



Table of Contents

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

Condensed Consolidated Statements of Stockholders’ Equity (Deficiency)

(continued)

 

 

 

Preferred Stock

 

Common Stock

 

Additional
Paid-In

 

Deferred
Stock
Based

 

Deficit
Accumulated
During
Development

 

Total
Stockholders’
Equity

 

Temporary
Equity—
Unregistered
Common Stock

 

 

 

Shares

 

Amount

 

Shares

 

Amount

 

Capital

 

Compensation

 

Stage

 

(Deficiency)

 

Shares

 

Amount

 

Balance, January 31, 2006

 

277,100

 

$

277

 

3,100,717

 

$

310

 

$

20,266,357

 

$

(1,045,971

)

$

(15,740,263

)

$

3,480,710

 

 

$

 

Conversion of Series A preferred stock and issuance of common stock

 

(174,000

)

(174

)

137,739

 

14

 

160

 

 

 

 

 

 

 

 

Implementation of ASC 718

 

 

 

 

 

 

 

 

 

(1,045,971

)

1,045,971

 

 

 

0

 

 

 

 

 

Private placement of common stock

 

 

 

 

 

125,787

 

13

 

943,388

 

 

 

 

 

943,401

 

 

 

 

 

Payment of selling agents fees and expenses in cash

 

 

 

 

 

 

 

 

 

(118,341

)

 

 

 

 

(118,341

)

 

 

 

 

Issuance of 15,779 warrants to selling agents

 

 

 

 

 

 

 

 

 

55,568

 

 

 

 

 

55,568

 

 

 

 

 

Selling agents warrants charged to cost of capital

 

 

 

 

 

 

 

 

 

(55,568

)

 

 

 

 

(55,568

)

 

 

 

 

Issuance of common stock and warrants for cash at $6.00 per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

166,667

 

1,000,000

 

Payment of finder’s fees and expenses in cash

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(80,000

)

Value of warrants classified as derivative financial instrument liability

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(15,000

)

Issuance of 27,425 units to finder

 

 

 

 

 

 

 

 

 

167,856

 

 

 

 

 

167,856

 

 

 

 

 

Common Stock issued for services

 

 

 

 

 

1,449

 

0

 

9,566

 

 

 

 

 

9,566

 

 

 

 

 

Value attributed to warrants issued with 6% convertible debentures

 

 

 

 

 

 

 

 

 

1,991,822

 

 

 

 

 

1,991,822

 

 

 

 

 

Reclassification of derivative financial instruments to stockholders’ equity upon adoption of ASC 815-40

 

 

 

 

 

 

 

 

 

567,085

 

 

 

(455,385

)

111,700

 

 

 

 

 

Warrants issued for services

 

 

 

 

 

 

 

 

 

101,131

 

 

 

 

 

101,131

 

 

 

 

 

Donated services

 

 

 

 

 

 

 

 

 

62,500

 

 

 

 

 

62,500

 

 

 

 

 

Stock based compensation

 

 

 

 

 

 

 

 

 

1,572,545

 

 

 

 

 

1,572,545

 

 

 

 

 

Preferred stock dividend

 

 

 

 

 

 

 

 

 

 

 

 

 

(59,164

)

(59,164

)

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,134,067

)

(7,134,067

)

 

 

 

 

Balance, January 31, 2007

 

103,100

 

$

103

 

3,365,692

 

$

337

 

$

24,518,098

 

$

0

 

$

(23,388,879

)

$

1,129,659

 

166,667

 

$

905,000

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

8



Table of Contents

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

Condensed Consolidated Statements of Stockholders’ Equity (Deficiency)

(continued)

 

 

 

Preferred Stock

 

Common Stock

 

Additional
Paid-In

 

Deficit
Accumulated
During
Development

 

Total
Stockholders’
Equity

 

Temporary Equity—
Unregistered
Common Stock

 

 

 

Shares

 

Amount

 

Shares

 

Amount

 

Capital

 

Stage

 

(Deficiency)

 

Shares

 

Amount

 

Balance, January 31, 2007

 

103,100

 

$

103

 

3,365,692

 

$

337

 

$

24,518,098

 

$

(23,388,879

)

1,129,659

 

166,667

 

$

905,000

 

Conversion of preferred stock to common stock

 

(7,500

)

(7

)

7,813

 

1

 

6

 

 

 

 

 

 

 

 

Private placement of common stock

 

 

 

 

 

283,333

 

28

 

849,972

 

 

 

850,000

 

 

 

 

 

Payment of selling agent fees and expenses

 

 

 

 

 

 

 

 

 

(51,733

)

 

 

(51,733

)

 

 

 

 

Issuance of warrants to selling agents

 

 

 

 

 

 

 

 

 

45,403

 

 

 

45,403

 

 

 

 

 

Selling agent warrants charged to cost of capital

 

 

 

 

 

 

 

 

 

(45,403

)

 

 

(45,403

)

 

 

 

 

Derivative liability—warrants at issuance

 

 

 

 

 

 

 

 

 

(45,371

)

 

 

(45,371

)

 

 

 

 

Donated services

 

 

 

 

 

 

 

 

 

275,000

 

 

 

275,000

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

914,847

 

 

 

914,847

 

 

 

 

 

Preferred stock dividend

 

 

 

 

 

 

 

 

 

 

 

(35,054

)

(35,054

)

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(4,683,141

)

(4,683,141

)

 

 

 

 

Balance, December 31, 2007

 

95,600

 

$

96

 

3,656,838

 

$

366

 

$

26,460,819

 

$

(28,107,074

)

(1,645,793

)

166,667

 

$

905,000

 

Reclassification of common stock initially recorded as temporary equity

 

 

 

 

 

166,667

 

17

 

904,983

 

 

 

905,000

 

(166,667

)

(905,000

)

Private placement of common stock

 

 

 

 

 

330,682

 

33

 

1,144,967

 

 

 

1,145,000

 

 

 

 

 

Payment of selling agents fees and expenses

 

 

 

 

 

 

 

 

 

(74,500

)

 

 

(74,500

)

 

 

 

 

Conversion of debenture to common stock

 

 

 

 

 

31,214

 

3

 

93,638

 

 

 

93,641

 

 

 

 

 

Derivative liability—warrants at issuance

 

 

 

 

 

 

 

 

 

(201,122

)

 

 

(201,122

)

 

 

 

 

Donated services

 

 

 

 

 

 

 

 

 

390,750

 

 

 

390,750

 

 

 

 

 

Stock based compensation

 

 

 

 

 

 

 

 

 

543,697

 

 

 

543,697

 

 

 

 

 

Preferred stock dividend

 

 

 

 

 

 

 

 

 

 

 

(38,240

)

(38,240

)

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(5,166,240

)

(5,166,240

)

 

 

 

 

Balance, December 31, 2008

 

95,600

 

$

96

 

4,185,401

 

$

419

 

$

29,263,232

 

$

(33,311,554

)

$

(4,047,807

)

0

 

$

0

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

9



Table of Contents

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

Condensed Consolidated Statements of Stockholders’ Equity (Deficiency)

(continued)

 

 

 

Preferred Stock

 

Common Stock

 

Additional
Paid-In

 

Deficit
Accumulated
During
Development

 

Total
Stockholders’
Equity

 

 

 

Shares

 

Amount

 

Shares

 

Amount

 

Capital

 

Stage

 

(Deficiency)

 

Balance December, 31, 2008

 

95,600

 

$

96

 

4,185,401

 

$

419

 

$

29,263,232

 

$

(33,311,554

)

$

(4,047,807

)

Issuance of shares of common stock in connection with convertible debenture forbearance agreement

 

 

 

 

 

906,245

 

91

 

1,739,868

 

 

 

1,739,959

 

Issuance of shares of common stock in payment of convertible debenture interest

 

 

 

 

 

60,147

 

6

 

112,285

 

 

 

112,291

 

Private placements of common stock

 

 

 

 

 

488,333

 

49

 

1,464,951

 

 

 

1,465,000

 

Issuance of common stock pursuant to a non-exclusive selling agent’s agreement

 

 

 

 

 

68,897

 

7

 

306,730

 

 

 

306,737

 

Issuance of shares of common stock re settlement for consulting services rendered

 

 

 

 

 

159,630

 

16

 

478,874

 

 

 

478,890

 

Stock based compensation expense

 

 

 

 

 

 

 

 

 

177,836

 

 

 

177,836

 

Preferred stock dividend

 

 

 

 

 

 

 

 

 

 

 

(38,240

)

(38,240

)

Derivative liability—warrants and price protected units upon issuance

 

 

 

 

 

 

 

 

 

(1,497,568

)

 

 

(1,497,568

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(2,483,807

)

(2,483,807

)

Balance, December 31, 2009

 

95,600

 

$

96

 

5,868,653

 

$

588

 

$

32,046,208

 

$

(35,833,601

)

$

(3,786,709

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

10



Table of Contents

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

Condensed Consolidated Statements of Stockholders’ Equity (Deficiency)

(continued)

 

 

 

Preferred Stock

 

Common Stock

 

Additional
Paid-In

 

Accumulated
Deficit
During
Development

 

Total
Stockholders’
Equity

 

 

 

Shares 

 

Amount

 

Shares 

 

Amount

 

Capital

 

Stage

 

(Deficiency)

 

Balance, December 31, 2009

 

95,600

 

$

96

 

5,868,653

 

$

588

 

$

32,046,208

 

(35,833,601

)

$

(3,786,709

)

Issuance of shares of common stock in payment of convertible debenture interest

 

 

 

 

 

85,619

 

9

 

115,962

 

 

 

115,971

 

Issuance of common stock to selling agents

 

 

 

 

 

79,333

 

8

 

(8

)

 

 

 

Private placement of units

 

 

 

 

 

578,233

 

58

 

1,734,642

 

 

 

1,734,700

 

Derivative liabilitiy—price protected units upon issuance

 

 

 

 

 

 

 

 

 

(1,010,114

)

 

 

(1,010,114

)

Consulting services settled via issuance of stock

 

 

 

 

 

70,833

 

7

 

212,493

 

 

 

212,500

 

Shares issued in settlement of legal fees

 

 

 

 

 

29,240

 

3

 

99,997

 

 

 

100,000

 

Stock issued in payment of deferred salary to former CEO

 

 

 

 

 

12,745

 

1

 

28,345

 

 

 

28,346

 

Shares issued in connection with Agreement & Plan of Merger with Etherogen, Inc.

 

 

 

 

 

2,043,797

 

204

 

2,771,185

 

 

 

2,771,389

 

Stock Based Compensation expense

 

 

 

 

 

 

 

 

 

325,930

 

 

 

325,930

 

Preferred stock dividend

 

 

 

 

 

 

 

 

 

 

 

(38,240

)

(38,240

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(5,449,138

)

(5,449,138

)

Balance, December 31, 2010

 

95,600

 

$

96

 

8,768,453

 

$

878

 

$

36,324,640

 

$

(41,320,979

)

$

(4,995,365

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

11



Table of Contents

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

Condensed Consolidated Statements of Stockholders’ Equity (Deficiency)

(continued)

 

 

 

Preferred
Stock
Shares

 

Preferred
Stock
Amount

 

Common
Stock
Shares

 

Common
Stock
Amount

 

Additional
Paid-In
Capital

 

Deficit
Accumulated
During
Development
Stage

 

Total
Stockholders’
Equity
(Deficiency)

 

Balance, December 31, 2010

 

95,600

 

$

96

 

8,768,453

 

$

878

 

$

36,324,640

 

$

(41,320,979

)

$

(4,995,365

)

Issuance of shares of common stock in payment of convertible debenture interest in accordance with Forbearance Agreement

 

 

 

 

 

64,214

 

6

 

85,269

 

 

 

85,275

 

Private placement of units

 

 

 

 

 

857,833

 

85

 

2,573,415

 

 

 

2,573,500

 

Derivative liability-fair value of warrants and price protected units issued

 

 

 

 

 

 

 

 

 

(1,298,618

)

 

 

(1,298,618

)

Shares issued in connection with Board Compensation

 

 

 

 

 

41,750

 

4

 

125,246

 

 

 

125,250

 

Issuance of common stock to shareholder as finder’s fees

 

 

 

 

 

90,258

 

9

 

(9

)

 

 

 

Issuance of common stock in connection with consulting services

 

 

 

 

 

58,333

 

6

 

174,994

 

 

 

175,000

 

Stock issued in connection with conversion of convertible debentures

 

 

 

 

 

856,185

 

85

 

1,130,079

 

 

 

1,130,164

 

Stock based compensation

 

 

 

 

 

 

 

 

 

250,978

 

 

 

250,978

 

Preferred stock dividend

 

 

 

 

 

 

 

 

 

 

 

(38,240

)

(38,240

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(2,239,212

)

(2,239,212

)

Balance, December 31, 2011

 

95,600

 

$

96

 

10,737,026

 

$

1,073

 

$

39,365,994

 

$

(43,598,431

)

$

(4,231,268

)

Units issued via registered underwritten direct public offering and private placement of units

 

 

 

 

 

4,383,333

 

438

 

16,899,562

 

 

 

16,900,000

 

Fees and expenses related to financing transactions

 

 

 

 

 

 

 

 

 

(1,576,452

)

 

 

(1,576,452

)

Derivative liability-fair value of warrants and price protected units issued

 

 

 

 

 

 

 

 

 

(1,796,610

)

 

 

(1,796,610

)

Correction of error in derivative liability—fair value of warrants price protected units issued

 

 

 

 

 

 

 

 

 

274,967

 

 

 

274,967

 

Warrants reclassified to additional paid in capital

 

 

 

 

 

 

 

 

 

3,317,463

 

 

 

3,317,463

 

Issuance of common stock and warrant to shareholder as finder’s fees

 

 

 

 

 

214,100

 

21

 

(21

)

 

 

 

Issuance of common stock in connection with Asset Purchase Agreement with MultiGen Diagnostics, Inc.

 

 

 

 

 

125,000

 

13

 

187,487

 

 

 

187,500

 

Issuance of common stock in connection with consulting services

 

 

 

 

 

9,916

 

1

 

22,380

 

 

 

22,381

 

Issuance of warrants in connection with advisory services

 

 

 

 

 

 

 

 

 

142,508

 

 

 

142,508

 

Stock based compensation

 

 

 

 

 

 

 

 

 

532,140

 

 

 

532,140

 

Issuance of common stock upon exercise of stock options

 

 

 

 

 

200

 

 

600

 

 

 

600

 

Issuance of common stock upon net exercise of warrant

 

 

 

 

 

8,602

 

1

 

(1

)

 

 

 

Preferred stock dividend

 

 

 

 

 

 

 

 

 

 

 

(38,240

)

(38,240

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(11,565,961

)

(11,565,961

)

Balance, December 31, 2012

 

95,600

 

$

96

 

15,478,177

 

$

1,547

 

$

57,370,017

 

$

(55,202,632

)

$

2,169,028

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

12



Table of Contents

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

Condensed Consolidated Statements of Stockholders’ Equity (Deficiency)

(continued)

 

 

 

Preferred
Stock
Shares

 

Preferred
Stock
Amount

 

Common
Stock
Shares

 

Common
Stock
Amount

 

Additional
Paid-In
Capital

 

Deficit
Accumulated
During
Development
Stage

 

Total
Stockholders’
Equity
(Deficiency)

 

Balance, December 31, 2012

 

95,600

 

$

96

 

15,478,177

 

$

1,547

 

$

57,370,017

 

$

(55,202,632

)

$

2,169,028

 

Issuance of warrants in connection with services

 

 

 

 

 

 

 

 

 

198,791

 

 

 

198,791

 

Stock based compensation

 

 

 

 

 

 

 

 

 

217,924

 

 

 

217,924

 

Issuance of common stock upon conversion of preferred stock

 

(17,500

)

(18

)

18,229

 

2

 

16

 

 

 

 

Issuance of common stock upon net exercise of warrant

 

 

 

 

 

7,284

 

1

 

(1

)

 

 

 

Issuance of common stock upon exercise of warrants

 

 

 

 

 

12,501

 

1

 

66,504

 

 

 

66,505

 

Preferred stock dividend

 

 

 

 

 

 

 

 

 

 

 

(5,885

)

(5,885

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(1,110,696

)

(1,110,696

)

Balance, March 31, 2013 (unaudited)

 

78,100

 

$

78

 

15,516,191

 

$

1,551

 

$

57,853,251

 

$

(56,319,213

)

$

1,535,667

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

13



Table of Contents

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

 

Condensed Consolidated Statements of Cash Flows

 

 

 

Three Months
ended March 31,
2013

 

Three Months
ended March 31,
2012

 

For the period
August 4, 1999
(Inception) to
March 31, 2013

 

 

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

 

 

 

 

 

 

 

 

Operating activities

 

 

 

 

 

 

 

Net loss

 

$

(1,110,696

)

$

(1,162,642

)

$

(54,718,829

)

 

 

 

 

 

 

 

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

17,779

 

6,190

 

277,420

 

Stock based compensation expense

 

540,266

 

102,830

 

12,552,731

 

Founders compensation contributed to equity

 

 

 

1,655,031

 

Donated services contributed to equity

 

 

 

829,381

 

Settlement of consulting services in stock

 

 

 

478,890

 

Amortization of deferred debt costs and original issue discount

 

 

 

2,346,330

 

Liquidated damages and other forbearance agreement settlement costs paid in stock

 

 

 

1,758,111

 

Interest expense on convertible debentures paid in stock

 

 

 

757,198

 

Change in fair value of financial instruments

 

(1,279,143

)

32,424

 

4,215,656

 

Gain on extinguishment of debt

 

 

 

(623,383

)

Purchased in process research and development expense-related party

 

 

 

2,666,869

 

Stock issued in connection with payment of deferred salary

 

 

 

28,346

 

Stock issued in connection with settlement of legal fees

 

 

 

100,000

 

Stock issued in connection with consulting services

 

 

 

452,389

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Increase in other assets

 

(156,694

)

 

(226,575

)

Decrease (increase) in accounts receivable

 

110,317

 

22,607

 

(58,065

)

(Increase) decrease in prepaid expenses

 

(67,043

)

217

 

(127,084

)

Increase in accounts payable and accrued expenses

 

316,554

 

93,286

 

995,173

 

Net cash used in operating activities

 

(1,628,660

)

(905,088

)

(26,640,411

)

 

 

 

 

 

 

 

 

Investing activities:

 

 

 

 

 

 

 

Assets acquired in Etherogen, Inc. merger

 

 

 

(104,700

)

Capital expenditures

 

(93,351

)

(98,009

)

(607,734

)

Net cash used in investing activities

 

(93,351

)

(98,009

)

(712,434

)

 

 

 

 

 

 

 

 

Financing activities:

 

 

 

 

 

 

 

Proceeds from sale of 6% convertible debenture

 

 

 

2,335,050

 

Debt issuance costs

 

 

 

(297,104

)

Proceeds from sale of common stock, net of expenses

 

 

889,500

 

32,755,551

 

Proceeds from exercise of warrants

 

66,505

 

 

66,505

 

Proceeds from exercise of stock options

 

 

 

600

 

Proceeds from a non-exclusive selling agent’s agreement

 

 

 

142,187

 

Costs associated with recapitalization

 

 

 

(362,849

)

Proceeds from sale of preferred stock

 

 

 

2,771,000

 

Payment of finders’ fee on preferred stock

 

 

 

(277,102

)

Redemption of common stock

 

 

 

(500,000

)

Payment of preferred stock dividends

 

 

 

(116,718

)

Net cash provided by financing activities

 

66,505

 

889,500

 

36,517,120

 

Net change in cash and equivalent-(decrease)increase

 

(1,655,506

)

(113,597

)

9,164,275

 

Cash and cash equivalents—Beginning of period

 

10,819,781

 

700,374

 

 

Cash and cash equivalents—End of period

 

$

9,164,275

 

$

586,777

 

$

9,164,275

 

 

14



Table of Contents

 

 

 

Three Months Ended
March 31, 2013

 

Three Months Ended
March 31, 2012

 

For the period
August 4, 1999
(Inception) to
March 31, 2013

 

 

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

 

 

 

 

 

 

 

 

Supplementary disclosure of cash flow activity:

 

 

 

 

 

 

 

Cash paid for taxes

 

$

7,650

 

$

 

$

7,650

 

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

 

$

 

$

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash investing and financing activities:

 

 

 

 

 

 

 

Conversion of preferred stock

 

$

 

$

 

$

 

Issuance of common stock upon conversion of preferred stock

 

$

 

$

 

$

 

Issuance of 41,750 shares of common stock for Board of Directors’ fees in lieu of cash payment

 

$

 

$

 

$

125,250

 

Conversion of $2,335,050 of 6% debentures

 

$

 

$

 

$

1,130,164

 

Issuance of 125,000 shares of common stock pursuant to Asset Purchase Agreement with MultiGen Diagnostics, Inc.

 

$

 

$

187,500

 

$

187,500

 

Issuance of 2,043,797 shares of common stock pursuant to Agreement and Plan of Merger with Etherogen, Inc.

 

$

 

$

 

$

2,771,389

 

Reclassification of derivative financial instruments to additional paid in capital

 

$

 

$

 

$

(3,317,463

)

Correction of error in derivative financial instruments

 

$

 

$

 

$

(274,967

)

Series A Preferred beneficial conversion feature accreted as a dividend

 

$

 

$

 

$

792,956

 

Issuance of common stock from net exercise of warrants

 

$

 

$

 

$

 

Preferred stock dividends accrued

 

$

5,885

 

$

9,560

 

$

197,085

 

Interest paid in common stock

 

$

 

$

 

$

1,325,372

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

15



Table of Contents

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

 

Notes to Condensed Consolidated Financial Statements

 

1. Business Overview, Basis of Presentation and Going Concern

 

Business Overview

 

Trovagene, Inc. (“Trovagene” or the “Company”) is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Trovagene’s primary focus is to leverage its urine-based (i.e. transrenal) testing platform to facilitate improvements in the fields of oncology, infectious disease, transplantation and prenatal genetics. The Company’s novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). Tr-DNAs and Tr-RNAs are fragments of nucleic acids derived from dying cells inside the body. The intact DNA is fragmented in dying cells and released into the blood stream. These fragments have been shown to cross the kidney barrier and can be detected in urine. In addition, there is evidence that some species of RNA or their fragments are stable enough to cross the renal barrier. These RNA can also be isolated from urine, detected and analyzed. The Company’s technology is applicable to all transrenal nucleic acids (Tr-NA). Trovagene’s patented technology uses safe, non-invasive, cost effective and simple urine collection which can be applied to a broad range of testing including: minimal residual disease progression, infectious disease screening, transplant monitoring and prenatal genetic testing. Trovagene’s technology is ideally suited to be used in developing molecular diagnostic assays that will allow physicians to provide very simple, non-invasive and convenient screening and monitoring tests for their patients by identifying specific biomarkers involved in the disease process. In March 2013, Trovagene introduced its first urine-based test designed for Human Papillomavirus (HPV) screening. If the Company is successful, its novel assays may facilitate improved testing compliance resulting in earlier diagnosis of disease, more targeted treatment which will be more cost effective, and improvements in the quality of life for the patient.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of Trovagene, which include its wholly owned subsidiary Xenomics, Inc., a California corporation (“Xenomics Sub”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated. Certain items in the comparable prior period’s financial statements have been reclassified to conform to the current period’s presentation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements as of December 31, 2012 and December 31, 2011 and for each of the two years ended December 31, 2012 and from inception (August 4, 1999) to December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2013.  The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2013, and for all periods presented herein, have been made. The results of operations for the periods ended March 31, 2013 and 2012 are not necessarily indicative of the operating results for the full year.

 

On May 24, 2012, the Board of Directors approved a 1-for-6 reverse stock split of the Company’s issued and outstanding common stock effective on May 29, 2012. All the relevant information relating to number of shares and per share information contained in these consolidated financial statements has been retrospectively adjusted to reflect the reverse stock split for all periods presented.

 

Going Concern

 

Trovagene’s condensed consolidated financial statements as of March 31, 2013 have been prepared under the assumption that Trovagene will continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to generate additional revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company will be required to raise additional capital within the next twelve months to complete the development and commercialization of current product candidates and to continue to fund operations at its current cash expenditure levels.

 

Cash used in operating activities was $1,628,660 and $905,088, for the three months ended March 31, 2013 and 2012, respectively. During the three months ended March 31, 2013 and 2012, the Company incurred net loss of $1,110,696 and $1,162,642, respectively.

 

To date, Trovagene’s sources of cash have been primarily limited to the sale of debt and equity securities. Net cash provided by financing activities for the three months ended March 31, 2013 and March 31, 2012 was $66,505 and $889,500, respectively. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can

 

16



Table of Contents

 

raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct its business.

 

If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates. The Company may also be required to:

 

·                  Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and

 

·                  Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms.

 

The Company has approximately $8.6 million of cash at May 9, 2013.

 

2. Net Loss Per Share

 

Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. In a period where there is a net loss position, diluted weighted-average shares are the same as basic weighted-average shares. Shares used in calculating basic and diluted net loss per common share exclude as antidilutive the following share equivalents:

 

 

 

March 31,

 

 

 

2013

 

2012

 

Options to purchase Common Stock

 

3,962,710

 

2,971,192

 

Warrants to purchase Common stock

 

7,009,824

 

3,930,351

 

Series A Convertible Preferred Stock

 

81,354

 

99,583

 

 

 

 

 

 

 

 

 

11,053,888

 

7,001,126

 

 

3.              Accounting for Share-Based Payments

 

Stock Options

 

ASC Topic 718 “Compensation—Stock Compensation” requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. ASC Topic 718 did not change the way Trovagene accounts for non-employee stock-based compensation.Trovagene accounts for shares of common stock, stock options and warrants issued to non-employees based on the fair value of the stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received. The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payment to Non-Employees” whereas the value of the stock compensation is based upon the measurement date as determined at either: a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Accordingly the fair value of these options is being “marked to market” quarterly until the measurement date is determined.

 

Stock-based compensation expense related to Trovagene options have been recognized in operating results as follow:

 

 

 

Three Months
Ended March 31,

 

 

 

2013

 

2012

 

Included in research and development expense

 

$

122,317

 

$

7,583

 

Included in general and administrative expense

 

219,158

 

95,247

 

Total stock-based compensation expense

 

$

341,475

 

$

102,830

 

 

17



Table of Contents

 

The unrecognized compensation cost related to non-vested stock options outstanding at March 31, 2013 and 2012, net of expected forfeitures, was $3,504,395 and $875,885, respectively, to be recognized over a weighted-average remaining vesting period of approximately four years.

 

The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the following periods indicated.

 

 

 

Three Months
Ended
March
31, 2013

 

Three Months
Ended
March
31, 2012

 

Risk-free interest rate

 

0.82-0.89

%

1.04

%

Dividend yield

 

0

%

0

%

Expected volatility

 

97

%

90

%

Expected term (in years)

 

5.0 yrs.

 

5.0 yrs.

 

 

A summary of stock option activity and of changes in stock options outstanding under the Plan is presented below:

 

 

 

Number of
Options

 

Weighted Average
Exercise Price
Per Share

 

Intrinsic
Value

 

Balance outstanding, December 31, 2012

 

3,711,303

 

$

4.69

 

 

 

 

Granted

 

300,427

 

7.03

 

 

 

Forfeited

 

(49,020

)

4.55

 

 

 

Balance outstanding, March 31, 2013

 

3,962,710

 

$

4.87

 

$

2,513,114

 

Exercisable at March 31, 2013

 

1,926,328

 

$

5.85

 

$

2,300,760

 

 

The Company issued 156,877 options over the authorized number of options in the Plan.  As per ASC Topic 815-40, the options should be accounted for as liabilities and recorded at fair value with the changes in fair value being recorded in the Company’s statement of operations. Once stockholder approval is obtained to increase the number of authorized shares, the liability will then be reversed into additional paid in capital.  The Company has recorded $123,551 of stock based compensation and the liability for this amount in accrued expenses.

 

Warrants

 

A summary of warrant activity is presented below:

 

 

 

Number
of
Warrants

 

Weighted
Average
Exercise
price

 

Remaining
Contractual Term

 

Balance outstanding, December 31, 2012

 

6,985,070

 

$

3.96

 

 

 

Granted

 

50,000

 

 

8.00

 

 

 

Exercised

 

(25,246

)

4.15

 

 

 

Balance outstanding March 31, 2013

 

7,009,824

 

$

3.99

 

7 months - 5.75 years

 

 

The Company issued a warrant to purchase 50,000 shares of common stock at an exercise price of $8.00 per share, in the three months ended March 31, 2013.  The warrants were issued in connection with an agreement to provide services related to investor and public relations materials and expire three years from date of grant.  The estimated fair value of the warrant was determined on the date of grant using the Black-Scholes option valuation model using the following assumptions:  a risk-free interest rate of 0.42%, dividend yield of 0%, expected volatility of 97% and expected term of three years.  The resulting fair value of $198,791 was recorded as stock based compensation expense.

 

4.              Stockholders’ Equity (Deficiency)

 

Common Stock

 

During the three month period ended March 31, 2013, the Company issued 19,785 shares of Common Stock upon exercise of warrants.  Of these shares, 12,501 were issued at an exercise price of $5.32.  The remaining 7,284 were purchased upon net exercise of 12,745 warrants at an exercise price of $3.00.

 

18



Table of Contents

 

Series A Convertible Preferred Stock

 

During the first quarter of 2013, 17,500 shares of Series A Convertible Preferred Stock were converted into 18,229 shares of common stock, on a net converted basis.  As of March 31, 2013, 78,100 shares of Series A Convertible Preferred were outstanding.

 

5. Asset Purchase Agreement

 

On February 1, 2012 the Company entered into an asset purchase agreement with MultiGen Diagnostics, Inc.  The Company determined that the acquired asset does not meet the definition of a business, as defined in ASC 805, Business Combinations and will be accounted for under ASC 350, Intangibles- Goodwill and Other.  In connection with the acquisition, the Company issued 750,000 shares of restricted common stock to MultiGen.  In addition, up to an additional $3.7 million may be paid in a combination of common stock and cash to MultiGen upon the achievement of specific sales and earnings targets. In addition, in connection with the acquisition, the Company entered into a Reagent Supply Agreement dated as of February 1, 2012 pursuant to which MultiGen will supply and deliver reagents to be used in connection with a Clinical Laboratory Improvement Amendment (CLIA) laboratory.  The total purchase consideration was determined to be $187,500 which was paid in the Company’s common stock.

 

Under ASC Topic 805, Business Combinations, the Company was required to assess the fair value of the assets acquired and the contingent consideration at the date of acquisition. Therefore, the Company assessed the fair value of the assets purchased and concluded that the purchase price would be allocated entirely to one intangible asset, a CLIA license.  The contingent consideration of the $3.7 million milestone was determined to have no fair value by applying a weighted average probability on the achievement of the milestones developed during the valuation process.  The Company will assess the fair value of the contingent consideration at each quarter and make adjustments as necessary until the milestone dates have expired.  As of March 31, 2013, no adjustments to the fair value of the contingent consideration have been necessary, and therefore the fair value of the contingent consideration remains unchanged.

 

6.  Derivative Financial Instruments - Warrants

 

Effective January 1, 2009, the Company adopted provisions of ASC Topic 815-40, “Derivatives and Hedging: Contracts in Entity’s Own Equity” (“ASC Topic 815-40”). ASC Topic 815-40 clarifies the determination of whether an instrument issued by an entity (or an embedded feature in the instrument) is indexed to an entity’s own stock, which would qualify as a scope exception under ASC Topic 815-10.

 

Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Trovagene has determined that the warrants issued in connection with certain of its private placements and with its debentures must be recorded as derivative liabilities. Accordingly the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant changes in fair value is being recorded in the Company’s statement of operations.

 

The Company estimates the fair value of the warrants issued in connection with certain of its private placements and with its debentures using the Black-Scholes model in order to determine the associated derivative instrument liability and change in fair value described above. The range of assumptions used to determine the fair value of the warrants at the end of each three month period, March 31, 2013 and 2012 were as follows:

 

 

 

Three Months Ended
March 31, 2013

 

Three Months Ended
March 31, 2012

 

Estimated fair value of Trovagene common stock

 

$

6.26

 

$

1.50

 

Expected warrant term

 

0.82 – 5.76 years

 

5 years

 

Risk-free interest rate

 

0.11-1.01%

 

1.04%

 

Expected volatility

 

97%

 

90%

 

Dividend yield

 

0%

 

0%

 

 

The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Black-Scholes option pricing method, for the periods indicated:

 

Date

 

Description

 

Warrants

 

Derivative
Instrument
Liability

 

 

 

 

 

 

 

 

 

December 31, 2012

 

Balance of derivative financial instruments liability

 

1,087,060

 

$

6,252,760

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrants during the quarter recognized as a gain in the statement of operations

 

 

(727,113

)

 

 

 

 

 

 

 

 

March 31, 2013

 

Balance of derivative financial instruments liability

 

1,087,060

 

$

5,525,647

 

 

19



Table of Contents

 

The Company has issued units that were price protected. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Trovagene has determined that these price protected units issued in connection with the private placements must be recorded as derivative liabilities. Accordingly the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant changes in fair value is being recorded in the Company’s statement of operations. The fair value of these price protected units was estimated using the binomial option pricing model. The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which unit holders are likely to exercise their warrants and the expected forfeiture rate. The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model. The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.

 

The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Binomial option pricing method, for the periods indicated:

 

Date

 

Number of
Price Protected
Units

 

Derivative
Liability For
Issued Units

 

Change In
Fair
value of
Derivative
Liability For
Previously
Outstanding
Price
Protected
Units

 

Ending
Balance
Derivative
Liability

 

December 31, 2012

 

1,288,650

 

$

1,171,463

 

$

1,341,405

 

$

2,512,868

 

Change in fair value of warrants during the quarter recognized as a gain in the statement of operations

 

 

 

(552,030

)

(552,030

)

March 31, 2013

 

1,288,650

 

$

1,171,463

 

$

789,375

 

$

1,960,838

 

 

At March 31, 2013 and December 31, 2012, the total fair value of the above warrants accounted for as derivative financial instruments, valued using the Black-Scholes option-pricing model and the Binomial option pricing model was $7,486,485 and $8,765,628, respectively, and is classified as derivative financial instruments liability on the balance sheet.

 

7. Fair Value Measurements

 

Fair value of financial instruments

 

The Company has adopted FASB ASC 820 Fair Value Measurements and Disclosures (“ASC 820”) for financial assets and liabilities that are required to be measured at fair value, and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis. Financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. These financial instruments are stated at their respective historical carrying amounts which approximate fair value due to their short term nature.

 

The following tables present the Company’s liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2012 and March 31, 2013:

 

Description

 

Quoted Prices
in
Active
Markets
for Identical
Assets and
Liabilities
(Level 1)

 

Significant
Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Balance as of
December 31, 2012

 

Derivative liabilities related to Warrants

 

$

 

$

 

$

8,765,628

 

$

8,765,628

 

 

Description

 

Quoted Prices
in
Active
Markets
for Identical
Assets and
Liabilities
(Level 1)

 

Significant
Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Balance as of
March 31,
2013

 

Derivative liabilities related to Warrants

 

$

 

$

 

$

7,486,485

 

$

7,486,485

 

 

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2013:

 

Description 

 

Balance at
December 31,
2012

 

Unrealized
(gains) or
losses

 

Balance as of
March 31,
2013

 

Derivative liabilities related to Warrants

 

$

8,765,628

 

$

(1,279,143

)

$

7,486,485

 

 

20



Table of Contents

 

The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities in the Company’s statement of operations. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

 

21



Table of Contents

 

8. Commitments and Contingencies

 

Research and Development Agreements

 

During 2012, the Company entered into  research agreements with University of Texas MD Anderson Cancer Center (“MDACC”) to provide samples and evaluate methods used by the Company in identification of pancreatic cancer mutations, as well as to measure the degree of concordance between results of transrenal DNA mutations analysis from urine samples and tumor tissue.  Under these agreements, the Company has committed to pay $152,900 for the services performed by the University.  As of March 31, 2013, the Company has incurred $78,990 related to these agreements.

 

Employment Agreement

 

In January 2013, the Company entered into an employment agreement with Mark Erlander, Ph.D. in which he agreed to serve as Chief Scientific Officer.  Dr. Erlander’s salary is $200,000 per year. Dr. Erlander is eligible to receive a cash bonus of up to 50% of his base salary per year at the discretion of the Compensation Committee based on goals mutually agreed upon by Dr. Erlander, the CEO and the Board of Directors.  In connection with his employment, Dr. Erlander was granted a stock option to purchase 200,000 shares of common stock at an exercise price of $7.04.  The option vests ratably over a four year period.  If the Company terminates Dr. Erlander without cause, he is entitled to severance benefits equal to six months of his base salary.

 

Public Offering and Controlled Equity Offering

 

On January 25, 2013 the Company filed a Form S-3 Registration Statement to offer and sell in one or more offerings, any combination of common stock, preferred stock, warrants, or units having an aggregate initial offering price not exceeding $150,000,000. The preferred stock, warrants, and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other Trovagene securities.  This form was declared effective on February 4, 2013.  In addition, in connection with the Form S-3, the Company entered into an agreement with Cantor Fitzgerald & Co. (“Agent”) on January 25, 2013 to issue and sell up to $30,000,000 of shares of common stock through them.  As payment for its services, the Agent is entitled to a 3% commission on gross proceeds. No amounts have been raised to date relating to this agreement.

 

9. Subsequent Events

 

Research and Development Agreement

 

On April 25, 2013 the Company entered into a Research and Development Agreement with PerkinElmer Health Sciences, Inc. (“PerkinElmer”) pursuant to which the Company will design an assay, based on the Company’s TrNA technology, to determine the risk for developing hepatocellular carcinoma. The Company and PerkinElmer will jointly validate the assay and evaluate the potential of combining the Company’s TrNA technology with PerkinElmer’s technology for automation of nucleic acid isolation.  PerkinElmer will pay the Company certain milestone payments.  To date, no milestones have been met. In addition, the Company has granted PerkinElmer an exclusive option (the “HCC Option”) to obtain an exclusive royalty-bearing license to use the Company’s technology within the hepatocellular carcinoma field (the “HCC Field”).  Such option is exercisable within 15 days of the end of proof of principle work on the hepatocellular carcinoma assay.  In the event PerkinElmer exercises such option, the Company and PerkinElmer shall have a 60 day period to negotiate a license agreement.  If both parties cannot agree on the terms of a license agreement during such period, for a period of one year, and if the Company wishes to enter into a license agreement with a third party pursuant to which the Company shall grant to such third party a license on terms that are in the aggregate more favorable to the Company than the terms last offered by the Company to PerkinElmer, then the Company shall, prior to entering into such license agreement, first offer to enter into such license agreement with PerkinElmer instead of such third party.

 

The Company has also granted PerkinElmer an exclusive option to obtain an exclusive royalty-bearing license to use the Company’s technology in other fields. Such option is exercisable within 15 days of the completion of the proof of principle work for the HCC assay development.  In the event PerkinElmer exercises such option, the Company and PerkinElmer shall have a 60 day period to negotiate a license agreement.  If both parties cannot agree on the terms of a license agreement during such period or the option is not exercised by PerkinElmer, the Company shall be free to license such technology to any party.

 

22



Table of Contents

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions.

 

In addition, our business and financial performance may be affected by the factors that are discussed under “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2012, filed on April 1, 2013. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

 

You should not rely upon forward looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

 

The following discussion and analysis should be read in conjunction with our financial statements, included herewith. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management.

 

Overview

 

From August 4, 1999 (inception) through March 31, 2013 we have sustained a cumulative total deficit of $56,319,213.  From inception through March 31, 2013, we have generated minimal revenues and expect to incur additional losses to perform further research and development activities, We recently announced the launch of our first commercial product, a urine-based human papillomavirus (HPV) test.

 

Our product development  and commercialization efforts are in their early stages and we cannot make estimates of the costs or the time they will take to complete. The risk of completion of any program is high because of the many uncertainties involved in bringing new diagnostic products to market including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, the extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of research and development expenses and competing technologies being developed by organizations with significantly greater resources.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements.

 

Inflation

 

It is our opinion that inflation has not had a material effect on our operations.

 

23



Table of Contents

 

Critical Accounting Policies

 

Royalty and License Revenues

 

We license and sublicense our patent rights to healthcare companies, medical laboratories and biotechnology partners.  These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized for each element when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.

 

·                  Up-front nonrefundable license fees pursuant to agreements under which we have no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured.

 

·                  Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured.

 

·                  Milestone payments are recognized when both the milestone is achieved and the related payment is received.

 

Derivative Financial Instruments-Warrants

 

Our derivative liabilities are related to warrants issued in connection with financing transactions and are therefore not designated as hedging instruments.  All derivatives are recorded on our balance sheet at fair value in accordance with current accounting guidelines for such complex financial instruments.

 

We have issued common stock warrants in connection with the execution of certain equity and debt financings. Such warrants are classified as derivative liabilities under the provisions of FASB ASC 815 Derivatives and Hedging (“ASC 815”), and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is: (1) indexed to its own stock, and (2) classified in stockholders’ equity. Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.”

 

Research and Development

 

Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, regulatory and scientific consulting fees, as well as contract research and insurance, are accounted for in accordance with ASC Topic 730-10-55-2, Research and Development. Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense.  Costs are not allocated to projects as the majority of the costs relate to employees and facilities costs and we do not track employees’ hours by project or allocate facilities costs on a project basis.

 

Share-based Compensation

 

Share-based compensation expense for employees and directors is recognized in the statement of operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes model. Share-based compensation recorded in our statement of operations is based on awards expected to ultimately vest and has been reduced for estimated forfeitures.  We recognize the value of the awards on a straight-line basis over the awards’ requisite service periods. The requisite service period is generally the time over which our share-based awards vest.

 

We account for equity instruments granted to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payment to Non-Employees” where the value of the share-based compensation is based upon the measurement date as determined at either: a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete.  Accordingly the fair value of these options is being “marked to market” quarterly until the measurement date is determined.

 

Fair value of financial instruments

 

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and derivative liabilities. We have adopted FASB ASC 820 Fair Value Measurements and Disclosures (“ASC 820”) for financial assets and liabilities that are required to be measured at

 

24



Table of Contents

 

fair value, and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their respective historical carrying amounts which approximate to fair value due to their short term nature.

 

ASC 820 provides that the measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy:

 

· Level 1 — Quoted prices for identical instruments in active markets.

 

· Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.

 

· Level 3 — Instruments where significant value drivers are unobservable to third parties.

 

RESULTS OF OPERATIONS

 

Three Months Ended March 31, 2013 and 2012

 

Revenues

 

Our total revenues were $119,123 and $34,153 for the three months ended March 31, 2013 and 2012, respectively, and consisted of royalty income.  Royalty income increased by $84,970 in the three months ended March 31, 2013, due to an increase of approximately $72,000 in actual royalties received in excess of minimum royalties, with the remainder of the increase resulting from two  agreements that did not have any revenues in the three months ended March 31, 2012.

 

Research and Development Expenses

 

Research and development expenses consisted of the following:

 

 

 

For the three months ended March 31,

 

 

 

2013

 

2012

 

Increase

 

Salaries and staff costs

 

$

426,629

 

$

169,893

 

$

256,736

 

Outside services, consultants and lab supplies

 

268,642

 

86,802

 

181,840

 

Facilities

 

91,762

 

78,678

 

13,084

 

Other

 

15,212

 

2,034

 

13,178

 

Total research and development

 

$

802,245

 

$

337,407

 

$

464,838

 

 

Research and development expenses increased by $464,838 to $802,245 for the three months ended March 31, 2013 from $337,407 for the same period in 2012.  Substantially all of the increase resulted from the increases in salaries and staff costs and outside services, consultants and lab supplies as we expanded our research and development efforts to support the clinical collaborations entered into during 2012 related to detection of certain types of cancer in urine samples.  The increase in salaries and staff costs was comprised of approximately $217,000 from an increase of five employees and approximately $40,000 from the recruitment of two employees.  Outside services, consultants and lab supplies increased in the three months ended March 31, 2013, as compared to the same period in the prior year, primarily due to an increase of approximately $161,000 in lab supplies, samples and research agreements and approximately $20,000 resulting from additional consulting related to our CLIA lab.

 

General and Administrative Expenses

 

General and administrative expenses consisted of the following:

 

 

 

For the three months ended March 31,

 

 

 

2013

 

2012

 

Increase

 

Salaries and staff costs

 

$

721,368

 

$

129,948

 

$

591,420

 

Outside services and Board of Director fees

 

443,124

 

291,543

 

151,581

 

Legal and accounting fees

 

336,151

 

328,856

 

7,295

 

Facilities

 

47,593

 

24,123

 

23,470

 

Insurance

 

27,780

 

17,548

 

10,232

 

Other

 

130,701

 

34,946

 

95,755

 

 

 

$

1,706,717

 

$

826,964

 

$

879,753

 

 

25



Table of Contents

 

General and administrative expenses increased by $879,753 to $1,706,717 for the three months ended March 31, 2013, from $826,964 for the same period in 2012. This overall increase was primarily due to an increase in salaries and staff costs, outside services and Board of Director fees and other expenses from building our sales, marketing and business development infrastructure in preparation of upcoming launch and commercialization of our diagnostic products.  The increase in salaries and staff costs resulted from the addition of five employees in the three month period ended March 31, 2013 as compared to the same period of the prior year.  The increase in outside services and Board of Director fees was comprised of approximately $66,000 increase in Business Development, Sales and Market research services, an increase of approximately $50,000 related to Edgar and XBRL fees for our SEC documents, an approximate $26,000 increase in fees paid to our Board of Directors, and most of the remaining increase was attributed to increased payroll processing and set up fees due to the increase in the number of personnel in comparison to the prior year.   Other expenses increased by approximately $96,000 primarily as a result of increased travel, tax filing fees and attendance at meetings and conferences.

 

Change in Fair Value of Derivative Instruments - Warrants

 

We have issued securities that are accounted for as derivative liabilities.    As of March 31, 2013, the derivative liabilities related to securities issued were revalued to $7,486,485, resulting in a net decrease in value of $1,279,143 from December 31, 2012, based primarily upon the change in our stock price from $6.93 at December 31, 2012 to $6.26 at March 31, 2013 and the changes in the expected term and risk free interest rates for the expected term. The decrease in value was recorded as non-operating gain for the three months ended March 31, 2013.

 

Net Loss

 

Net loss and per share amounts were as follows:

 

 

 

For the three months ended March 31,

 

 

 

2013

 

2012

 

Net loss and comprehensive loss attributable to common shareholders

 

$

1,116,581

 

$

1,172,202

 

 

 

 

 

 

 

Net loss per common share: basic and diluted

 

$

(0.07

)

$

(0.11

)

Weighted average shares: basic and diluted

 

15,510,340

 

11,001,679

 

 

The $55,621 decrease in net loss and $0.04 decrease in net loss per share in 2013 compared to 2012 reflected a slight increase in revenues, offset by an increase in operating expenses and a gain from the change in fair value in derivative liabilities.  Net loss per share in 2013 was also favorably impacted by the sale and issuance of 4.3 million shares of common stock resulting from the direct public offering in May 2012, private placements, and exercise of stock options and warrants.

 

LIQUIDITY AND CAPITAL RESOURCES

 

As of March 31, 2013, we had $9,164,275 in cash and cash equivalents.  Net cash used in operating activities for the three months ended March 31, 2013 was $1,628,660, compared to $905,088 for the three months ended March 31, 2012. Our use of cash was primarily a result of the net loss of $1,110,696  for the three months ended March 31, 2013, adjusted for non-cash items related to stock-based compensation of $540,266, depreciation and amortization of $17,779 and the gain from the change in fair value of derivatives of $1,279,143.  The changes in our operating assets and liabilities consisted of higher accounts payable and accrued expenses, prepaid expenses and other assets, and a decrease in accounts receivable.  At our current and anticipated level of operating loss, we expect to continue to incur an operating cash outflow for the next several years.

 

Investing activities consisted of purchases for capital equipment and intangible assets that used $93,351 in cash during the three months ended March 31, 2013, compared to $98,009 for the same period in 2012.

 

Net cash provided by financing activities was $66,505 during the three months ended March 31, 2013, compared to $889,500 in 2012. Financing activities during the three months ended March 31, 2013 were from proceeds related to the exercise of warrants, while in 2012 the net cash provided by financing activities were from proceeds received related to the sale of common stock.

 

As of March 31, 2013, and December 31, 2012, we had working capital of $8,173,063 and $10,317,833, respectively.  As of May 9, 2013, our working capital was $7,965,473.

 

26



Table of Contents

 

Our working capital requirements will depend upon numerous factors including but not limited to the nature, cost and timing of our research and development programs. We will be required to raise additional capital within the next twelve months to complete the development and commercialization of current product candidates, to fund the existing working capital deficit and to continue to fund operations at our current cash expenditure levels. To date, our sources of cash have been primarily limited to the sale of equity securities and debentures. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more of product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves on unfavorable terms.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

At the end of the period covered by this Quarterly Report on Form 10-Q, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.  Based on that evaluation, as of March 31, 2013, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are not effective, due to weaknesses in our internal controls over financial reporting. We are implementing remedial measures designed to address the ineffectiveness of our disclosure controls and procedures.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

27



Table of Contents

 

PART II

 

ITEM 1. LEGAL PROCEEDINGS.

 

We are not a party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of our business. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

 

ITEM 6. EXHIBITS.

 

Exhibit
Number

 

Description of Exhibit

 

 

 

10.1

 

Research and Development Agreement between PerkinElmer Health Sciences, Inc. and Trovagene, Inc. dated as of April 25, 2013.*

 

 

 

31.1

 

Certification of Chief Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Exchange Act.

 

 

 

31.2

 

Certification of Principal Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.

 

 

 

32.1

 

Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2

 

Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101

 

Financial statements from the quarterly report on Form 10-Q of the Company for the quarter ended March 31, 2013, filed on May 14, 2013, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Operations, (ii) the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Cash Flows (iv) the Condensed Consolidated Statement of Stockholders Equity (Deficit) and (v) the Notes to Consolidated Financial Statements tagged as blocks of text.

 


 

 

*Portions of this exhibit were omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to a request for confidential treatment.

 

28



Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

TROVAGENE, INC.

 

 

May 14, 2013

By:

/s/ Antonius Schuh

 

 

Antonius Schuh

 

 

Chief Executive Officer

 

 

 

 

 

 

 

TROVAGENE, INC.

 

 

 

May 14, 2013

By:

/s/ Stephen Zaniboni

 

 

Stephen Zaniboni

 

 

Chief Financial Officer

 

29